Literature DB >> 3743619

Fluocortolone: pharmacokinetics and effect on plasma cortisol level.

U Täuber, K Richter, H Matthes.   

Abstract

The pharmacokinetics of fluocortolone and its effect on plasma cortisol levels are described after oral administration of 20, 50 and 100 mg to 9 healthy adults. The concentrations of fluocortolone and cortisol in plasma were measured simultaneously by HPLC with UV detection. Fluocortolone was rapidly absorbed after all doses, giving the maximum plasma level after 1.4-2.1 h. After ingestion of 20, 50 and 100 mg, the peak levels were 199, 419 and 812 ng/ml, respectively. The maximum plasma levels and areas under the plasma level-time curves increased in proportion to the dose. Post-maximum plasma levels declined monoexponentially with a half-life of 1.76 h. Plasma half-life (t1/2 = 1.76 h), volume of distribution (1.03 l/kg) and oral clearance (6.9 ml/min/kg) were independent of the dose. The intensity and duration of adrenal suppression was dose dependent. Maximum suppression was observed 8 hours after fluocortolone. Clearcut suppression of cortisol levels after 24 hours was only seen following 100 mg fluocortolone.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3743619     DOI: 10.1007/bf00607956

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Glucocorticoid therapy.

Authors:  L Axelrod
Journal:  Medicine (Baltimore)       Date:  1976-01       Impact factor: 1.889

Review 2.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  M E Pickup
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

3.  The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration.

Authors:  U Täuber; D Haack; B Nieuweboer; G Kloss; P Vecsei; H Wendt
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-01

4.  Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration.

Authors:  H Bergrem; P Grøttum; H E Rugstad
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.

Authors:  J G Gambertoglio; W J Amend; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

6.  [The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)].

Authors:  H Gleispach; S Porta
Journal:  Wien Klin Wochenschr       Date:  1981-11-13       Impact factor: 1.704

7.  Dose dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J Q Rose; A M Yurchak; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

8.  [Metabolism of 6 -fluor-16 -methylpregna-1,4-dien-ll ,21-diol-3,20-dion (fluocortolone) in man. Isolation of 6 -hydroxylated metabolites (alkyl-substituted steroids VII)].

Authors:  E Gerhards; B Nieuweboer; G Schulz; H Gibian
Journal:  Acta Endocrinol (Copenh)       Date:  1971-09
  8 in total
  4 in total

1.  Lack of impairment of fluocortolone disposition in oral contraceptive users.

Authors:  U F Legler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Pharmacodynamic modeling of cortisol suppression from fluocortolone.

Authors:  K H Lew; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.

Authors:  B Meibohm; G Hochhaus; H Möllmann; J Barth; M Wagner; M Krieg; R Stöckmann; H Derendorf
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

4.  Fluocortolone: pharmacokinetics and effect on ACTH and cortisol secretion during daily and alternate-day administration.

Authors:  U Tüber; U Posern; U Bickel; H Matthes; K Voigt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.